

Larry W Kwak

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3297975/larry-w-kwak-publications-by-year.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

202
papers

11,466
citations

58
h-index

103
g-index

207
ext. papers

12,543
ext. citations

7.3
avg, IF

5.52
L-index

#	Paper	IF	Citations
202	CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia.. <i>Leukemia</i> , 2022 ,	10.7	2
201	Immortalized B Cells Transfected With mRNA of Antigen Fused to MITD (IBMAM): An Effective Immunological Tool for In-Vitro Immune-Monitoring of Antigen-specific T Cells. <i>JCO Global Oncology</i> , 2022 , 8, 21-21	3.7	
200	Targeted InVivo Delivery of NF-B Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy. <i>Molecular Therapy</i> , 2021 , 29, 1214-1225	11.7	1
199	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. <i>Cancer Immunology Research</i> , 2021 , 9, 75-88	12.5	10
198	Double-hit Signature with Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP. <i>Clinical Cancer Research</i> , 2021 , 27, 1671-1680	12.9	8
197	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 ,	2	2
196	Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. <i>Blood Advances</i> , 2021 , 5, 3354-3361	7.8	3
195	Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2139-2145	7.4	6
194	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020 , 26, 1034-1044	12.9	25
193	Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma. <i>Blood</i> , 2020 , 136, 27-28	2.2	0
192	A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering Waldenström Macroglobulinemia (sWM). <i>Blood</i> , 2020 , 136, 6-7	2.2	
191	The changing investment in translational science by academic medical centers: HOPE in the Valley of Death. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3333-3335	15.9	4
190	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	37
189	Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019 , 185, 670-678	4.5	4
188	Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. <i>Blood</i> , 2019 , 133, 306-318	2.2	16
187	B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. <i>Molecular Therapy</i> , 2018 , 26, 695-707	11.7	17
186	Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. <i>Cancer</i> , 2018 , 124, 2561-2569	6.4	11

185	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 87	22.4	8
184	Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. <i>BMC Cancer</i> , 2018 , 18, 187	4.8	9
183	Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 1636-1636	2.2	5
182	Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors. <i>Blood</i> , 2018 , 132, 1411-1411	2.2	5
181	Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies. <i>Clinical Cancer Research</i> , 2018 , 24, 1114-1123	12.9	19
180	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 514-520	4.7	27
179	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. <i>Lancet Haematology</i> , 2018 , 5, e543-e553	14.6	38
178	Targeting myeloid-derived suppressor cells for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1181-1195	7.4	75
177	Absence of Grail promotes CD8 T cell anti-tumour activity. <i>Nature Communications</i> , 2017 , 8, 239	17.4	16
176	CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. <i>Cancer Research</i> , 2017 , 77, 5118-5128	10.1	17
175	Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1861-1869	4.7	18
174	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. <i>Lancet Haematology</i> , 2017 , 4, e362-e373	14.6	58
173	Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. <i>Cell Research</i> , 2017 , 27, 1034-1045	24.7	147
172	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017 , 35, 24-31	2.2	105
171	Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2017 , 130, 738-738	2.2	5
170	Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7532-7532	2.2	1
169	Overview of lymphoma 2017 , 1-9		
168	Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. <i>Leukemia and Lymphoma</i> , 2016 , 57, 445-447	1.9	4

167	Targeting B-cell malignancies through human B-cell receptor specific CD4 T cells. <i>Oncolmmunology</i> , 2016 , 5, e1232220	7.2	5
166	Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL). <i>Blood</i> , 2016 , 128, 1807-1807	2.2	10
165	Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2016 , 128, 2943-2943	2.2	
164	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia 2016 , 4, 90		14
163	CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. <i>Immunity</i> , 2016 , 44, 913-923	32.3	94
162	IL-15 enhances the antitumor effect of human antigen-specific CD8 T cells by cellular senescence delay. <i>Oncolmmunology</i> , 2016 , 5, e1237327	7.2	14
161	Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. <i>British Journal of Haematology</i> , 2016 , 172, 80-8	4.5	67
160	Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. <i>British Journal of Haematology</i> , 2015 , 169, 689-93	4.5	28
159	Targeting tumor-associated myeloid cells for cancer immunotherapy. <i>Oncolmmunology</i> , 2015 , 4, e983967	7.2	7
158	Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 152-8	2	21
157	Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2015 , 100, e272-4	6.6	16
156	CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2015 , 171, 726-35	4.5	40
155	Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2015 , 171, 463-70	4.5	60
154	Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. <i>British Journal of Haematology</i> , 2015 , 169, 814-23	4.5	3
153	Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2015 , 171, 509-16	4.5	13
152	Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. <i>Blood</i> , 2015 , 126, 519-519	2.2	5
151	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 522-522	2.2	3
150	Anti-Emicroglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. <i>Oncotarget</i> , 2015 , 6, 8567-78	3.3	20

149	Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. <i>Oncotarget</i> , 2015 , 6, 34329-41	3.3	87
148	Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 1961-1961	3.2	221
147	The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014 , 165, 112-6	4.5	43
146	Osteoblastic niche supports the growth of quiescent multiple myeloma cells. <i>Blood</i> , 2014 , 123, 2204-8	2.2	53
145	Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. <i>Nature Medicine</i> , 2014 , 20, 676-81	50.5	148
144	Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1311-8	21.7	199
143	Double hit lymphoma: the MD Anderson Cancer Center clinical experience. <i>British Journal of Haematology</i> , 2014 , 166, 891-901	4.5	244
142	Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. <i>International Journal of Cancer</i> , 2014 , 135, 2834-46	7.5	26
141	The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. <i>Biomaterials</i> , 2014 , 35, 5491-504	15.6	84
140	Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. <i>Cancer Science</i> , 2014 , 105, 795-801	6.9	64
139	90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. <i>British Journal of Haematology</i> , 2014 , 167, 207-13	4.5	21
138	Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 69-77	21.7	441
137	Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes. <i>American Journal of Blood Research</i> , 2014 , 4, 46-52	1.6	4
136	Cloning variable region genes of clonal lymphoma immunoglobulin for generating patient-specific idiotypic DNA vaccine. <i>Methods in Molecular Biology</i> , 2014 , 1139, 289-303	1.4	2
135	Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 99-105	2	18
134	Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013 , 163, 611-20	4.5	20
133	The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 15-8	2	28
132	Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. <i>Journal of Immunology</i> , 2013 , 191, 3641-50	5.3	75

131	Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. <i>Haematologica</i> , 2013 , 98, 1458-66	6.6	42
130	In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2494-504	6.1	21
129	Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2013 , 162, 138-41	4.5	29
128	Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. <i>Journal of Immunology</i> , 2013 , 190, 4887-98	5.3	39
127	Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. <i>Clinical Cancer Research</i> , 2013 , 19, 6882-90	12.9	88
126	Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. <i>PLoS ONE</i> , 2013 , 8, e69126	3.7	28
125	Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. <i>PLoS ONE</i> , 2013 , 8, e82453	3.7	4
124	Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial. <i>Seminars in Oncology</i> , 2012 , 39, 253-62	5.5	7
123	Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. <i>Blood</i> , 2012 , 119, 2568-78	2.2	20
122	Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. <i>Blood</i> , 2012 , 119, 161-9	2.2	82
121	Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. <i>Blood</i> , 2012 , 120, 3783-92	2.2	82
120	Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. <i>British Journal of Haematology</i> , 2012 , 159, 243-6	4.5	7
119	Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. <i>Lancet Oncology, The</i> , 2012 , 13, 716-23	21.7	227
118	Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2012 , 53, 50-6	1.9	22
117	Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2776-82	2.2	147
116	Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. <i>Blood</i> , 2012 , 119, 4123-8	2.2	60
115	TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. <i>Blood</i> , 2012 , 120, 1613-23	2.2	27
114	MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. <i>Haematologica</i> , 2012 , 97, 586-94	6.6	92

113	Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. <i>Cancer</i> , 2012 , 118, 3793-800	6.4	76
112	Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. <i>Journal of Molecular Medicine</i> , 2012 , 90, 695-706	5.5	48
111	Bortezomib-resistant nuclear factor B expression in stem-like cells in mantle cell lymphoma. <i>Experimental Hematology</i> , 2012 , 40, 107-18.e2	3.1	16
110	Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4161-7	2.2	123
109	T cells and T cell tumors efficiently generate antigen-specific cytotoxic T cell immunity when modified with an NKT ligand. <i>Onc Immunology</i> , 2012 , 1, 141-151	7.2	2
108	p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. <i>Cancer Research</i> , 2012 , 72, 6393-402	10.1	58
107	Translational Development of Therapeutic Vaccines for Lymphoma 2012 , 203-206		
106	Translational development of vaccination strategies in follicular NHL. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 295-304	4.2	6
105	Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2011 , 154, 284-6	4.5	20
104	Targeting cell surface μ -microglobulin by pentameric IgM antibodies. <i>British Journal of Haematology</i> , 2011 , 154, 111-21	4.5	9
103	An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. <i>Journal of Controlled Release</i> , 2011 , 155, 184-92	11.7	66
102	Identification of human idiotype-specific T cells in lymphoma and myeloma. <i>Current Topics in Microbiology and Immunology</i> , 2011 , 344, 193-210	3.3	10
101	Cancer vaccines: moving toward prevention?. <i>Cancer Prevention Research</i> , 2011 , 4, 954-6	3.2	1
100	Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2787-94	2.2	193
99	Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4845-6	2.2	10
98	Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. <i>Clinical Cancer Research</i> , 2011 , 17, 5945-52	12.9	9
97	Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010 , 150, 200-8	4.5	168
96	Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010 , 151, 47-53	4.5	44

95	Prime-boost vaccination using chemokine-fused gp120 DNA and HIV envelope peptides activates both immediate and long-term memory cellular responses in rhesus macaques. <i>Journal of Biomedicine and Biotechnology</i> , 2010 , 2010, 860160		4
94	Effect of long-term storage in TRIzol on microarray-based gene expression profiling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2445-52	4	39
93	Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines. <i>Vaccine</i> , 2010 , 28, 7970-8	4.1	5
92	Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. <i>Stem Cell Research</i> , 2010 , 5, 212-25	1.6	21
91	Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. <i>Clinical Cancer Research</i> , 2009 , 15, 951-9	12.9	14
90	Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. <i>Blood</i> , 2009 , 114, 3880-9	2.2	25
89	IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. <i>Blood</i> , 2009 , 114, 360-70	2.2	43
88	Cancer vaccines: up, down, ¶p again?. <i>Blood</i> , 2009 , 113, 1-2	2.2	82
87	Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. <i>Blood</i> , 2009 , 114, 4142-9	2.2	29
86	Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2008 , 143, 355-60	4.5	86
85	A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. <i>Journal of Immunological Methods</i> , 2008 , 331, 13-26	2.5	14
84	Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. <i>Cancer Research</i> , 2008 , 68, 8456-64	10.1	51
83	A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. <i>Clinical Cancer Research</i> , 2008 , 14, 2154-60	12.9	24
82	Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells. <i>Molecular Therapy</i> , 2008 , 16, 2011-21	11.7	56
81	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. <i>Blood</i> , 2008 , 111, 5530-6	2.2	261
80	Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. <i>Cancer</i> , 2008 , 113, 791-8	6.4	193
79	Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. <i>Cancer</i> , 2008 , 113, 2734-41	6.4	29
78	Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. <i>American Journal of Hematology</i> , 2008 , 83, 144-9	7.1	15

77	Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2008 , 112, 3051-3051	2.2	5
76	Elevated serum BlyS levels in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1869-71	1.9	11
75	Therapeutic vaccine for lymphoma. <i>Yonsei Medical Journal</i> , 2007 , 48, 1-10	3	5
74	Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. <i>Cancer</i> , 2007 , 109, 77-83	6.4	44
73	Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. <i>Cancer</i> , 2007 , 109, 2481-9	6.4	124
72	Human C-reactive protein binds activating Fcγ receptors and protects myeloma tumor cells from apoptosis. <i>Cancer Cell</i> , 2007 , 12, 252-65	24.3	97
71	Vaccine therapy for B-cell lymphomas: next-generation strategies. <i>Hematology American Society of Hematology Education Program</i> , 2007 , 2007, 243-9	3.1	6
70	Prognostic significance of serum B-lymphocyte stimulator in Hodgkin lymphoma. <i>Haematologica</i> , 2007 , 92, 269-70	6.6	16
69	A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. <i>Blood</i> , 2007 , 109, 5407-10	2.2	17
68	An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. <i>Blood</i> , 2007 , 110, 2013-9	2.2	62
67	A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. <i>Blood</i> , 2007 , 109, 5160-3	2.2	30
66	Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. <i>Blood</i> , 2007 , 110, 3028-35	2.2	42
65	Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. <i>Vaccine</i> , 2007 , 25, 7955-61	4.1	32
64	Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. <i>Blood</i> , 2007 , 110, 1587-94	2.2	96
63	Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. <i>Cancer Cell</i> , 2006 , 10, 295-307	24.3	80
62	Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. <i>Journal of Controlled Release</i> , 2006 , 113, 261-70	11.7	75
61	Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera. <i>Journal of Immunological Methods</i> , 2006 , 312, 79-93	2.5	3
60	Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. <i>Journal of Infectious Diseases</i> , 2006 , 194, 1394-7	7	39

59	623. Polymer Microparticles Delivering a Idiotype/Chemokine Fusion DNA Vaccine Generate Protective Immunity in a Mice Model of B Cell Lymphoma. <i>Molecular Therapy</i> , 2006 , 13, S240	11.7	
58	Molecular analysis of light-chain switch and acute lymphoblastic leukemia transformation in two follicular lymphomas: implications for lymphomagenesis. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1523-34	1.9	30
57	Therapeutic lymphoma vaccines: importance of T-cell immunity. <i>Expert Review of Vaccines</i> , 2006 , 5, 381-392	3.4	16
56	Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. <i>Blood</i> , 2006 , 107, 2432-9	2.2	91
55	Myeloma wrecks Treg?. <i>Blood</i> , 2006 , 107, 8-9	2.2	
54	Optimizing immunotherapy in multiple myeloma: Restoring the function of patientsR monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. <i>Blood</i> , 2006 , 108, 4071-7	2.2	78
53	Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. <i>Blood</i> , 2006 , 108, 2407-15	2.2	60
52	Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.. <i>Blood</i> , 2006 , 108, 2742-2742	2.2	9
51	Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. <i>Clinical Lymphoma and Myeloma</i> , 2005 , 6, 61-4		25
50	B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. <i>Blood</i> , 2005 , 106, 795-802	2.2	98
49	Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. <i>Nature Medicine</i> , 2005 , 11, 986-91	50.5	93
48	Therapeutic idiotype vaccines in B lymphoproliferative diseases. <i>Expert Opinion on Biological Therapy</i> , 2004 , 4, 959-63	5.4	9
47	Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. <i>Clinical Cancer Research</i> , 2004 , 10, 8309-17	12.9	69
46	Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies. <i>Clinical Cancer Research</i> , 2004 , 10, 1047-56	12.9	18
45	Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. <i>Journal of Leukocyte Biology</i> , 2004 , 76, 77-85	6.5	23
44	Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. <i>Laboratory Investigation</i> , 2004 , 84, 235-44	5.9	79
43	Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. <i>Seminars in Oncology</i> , 2004 , 31, 37-46	5.5	17
42	Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry. <i>Proteomics</i> , 2004 , 4, 1195-203	4.8	125

41	A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. <i>Journal of Translational Medicine</i> , 2004 , 2, 9	8.5	32
40	Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. <i>Blood</i> , 2004 , 104, 1961-9	2.2	50
39	Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. <i>Journal of Clinical Investigation</i> , 2004 , 113, 1498-510	15.9	52
38	Human Autologous Tumor-Specific T-Cell Responses Induced by Liposome Encapsulated Lymphoma Membrane Proteins.. <i>Blood</i> , 2004 , 104, 749-749	2.2	2
37	Vaccination strategies for lymphomas. <i>Current Oncology Reports</i> , 2003 , 5, 380-6	6.3	5
36	Translational development of active immunotherapy for hematologic malignancies. <i>Seminars in Oncology</i> , 2003 , 30, 17-22	5.5	14
35	In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1201-8	1.9	14
34	Translational development of active immunotherapy for hematologic malignancies. <i>International Journal of Hematology</i> , 2002 , 76 Suppl 1, 320-1	2.3	
33	DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. <i>Blood</i> , 2002 , 100, 1153-9	2.2	117
32	Current Status of Recombinant Idiotype Vaccines for the Treatment of Follicular Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2002 , 3, 147-149		
31	Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. <i>Science</i> , 2002 , 298, 1025-9	33.3	796
30	Mammalian defensins in immunity: more than just microbicidal. <i>Trends in Immunology</i> , 2002 , 23, 291-6	14.4	572
29	Models for lymphoma. <i>Current Protocols in Immunology</i> , 2002 , Chapter 20, Unit 20.6	4	1
28	Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. <i>Haematologica</i> , 2002 , 87, 989-1001	6.6	43
27	Novel secondary Ig VH gene rearrangement and in-frame Ig heavy chain complementarity-determining region III insertion/deletion variants in de novo follicular lymphoma. <i>Journal of Immunology</i> , 2001 , 166, 2235-43	5.3	18
26	Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. <i>Journal of Immunology</i> , 2001 , 167, 6644-53	5.3	260
25	Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001 , 127 Suppl 2, R14-9	4.9	10
24	Immunotherapy of multiple myeloma. <i>Seminars in Hematology</i> , 2001 , 38, 260-7	4	19

23	Clinical trial designs for the early clinical development of therapeutic cancer vaccines. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1848-54	2.2	98
22	Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. <i>Blood</i> , 2000 , 96, 2828-2833	2.2	99
21	Approaches for immunotherapy of lymphomas. <i>Immunological Investigations</i> , 2000 , 29, 93-5	2.9	1
20	Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. <i>International Immunology</i> , 2000 , 12, 691-700	4.9	160
19	Serum BCL2/IGH DNA in follicular lymphoma patients: a minimal residual disease marker. <i>Leukemia and Lymphoma</i> , 2000 , 39, 165-72	1.9	8
18	Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. <i>Blood</i> , 2000 , 96, 2828-2833	2.2	6
17	Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. <i>Nature Medicine</i> , 1999 , 5, 1171-7	50.5	522
16	B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions. <i>Immunological Reviews</i> , 1999 , 170, 115-26	11.3	20
15	Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. <i>Nature Biotechnology</i> , 1999 , 17, 253-8	44.5	254
14	Mechanisms of resistance against B-cell malignancies induced by vaccination against the immunoglobulin receptor: the case for T-cell immunity. <i>Cancer Treatment and Research</i> , 1999 , 99, 267-73 ^{3,5}		1
13	Development of vaccine strategies for the treatment of B-cell malignancies. <i>Cancer Investigation</i> , 1997 , 15, 577-87	2.1	19
12	Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma [Long-Term Results of a Clinical Trial. <i>Blood</i> , 1997 , 89, 3129-3135	2.2	419
11	The current status of human cancer vaccines. <i>Expert Opinion on Investigational Drugs</i> , 1994 , 3, 1241-1253 ^{5,9}		2
10	Immunoglobulin idiotype antigen vaccines for the treatment of lymphomas. <i>Clinical Immunology Newsletter</i> , 1994 , 14, 121-124		
9	Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. <i>Journal of the National Cancer Institute</i> , 1993 , 85, 1294-302	9.7	61
8	MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices. <i>Cancer</i> , 1993 , 71, 4034-42	6.4	6
7	Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. <i>New England Journal of Medicine</i> , 1992 , 327, 1209-15	59.2	485
6	Clinical significance of morphologic subdivision in diffuse large cell lymphoma. <i>Cancer</i> , 1991 , 68, 1988-93 ^{6,4}		44

- 5 The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. *Annals of Oncology*, **1991**, 2 Suppl 1, 47-50 10.3 38
- 4 Follicular lymphoma: A model of lymphoid tumor progression in man. *Annals of Oncology*, **1991**, 2, 115-122.3 18
- 3 GENETICS AND IMMUNOLOGY OF THE P815-X2 MODEL11Supported by NIH Grants CA19791, CA27599, and CA27955 **1985**, 363-367
- 2 Immune response to the H-X antigen on P815-X2. I. Recombinant inbred strain analysis and lack of effect of castration. *Immunogenetics*, **1984**, 20, 481-91 3.2
- 1 Evidence for involvement of the H-2Kb and I-Ab genes in hybrid resistance to P815-X2. *Immunogenetics*, **1981**, 13, 351-3 3.2 5